Online citations, reference lists, and bibliographies.
← Back to Search

Duloxetine Versus Placebo In The Treatment Of Stress Urinary Incontinence.

P. Norton, N. Zinner, I. Yalcin, R. Bump
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE The purpose of this study was to assess the efficacy and safety of duloxetine, a selective inhibitor of serotonin and norepinephrine reuptake, in the treatment of stress urinary incontinence. STUDY DESIGN A double-blind, randomized, placebo-controlled study was conducted in 553 women aged 18 to 65 years with a predominant symptom of stress urinary incontinence. Subjects were randomized to placebo (n = 138 women) or duloxetine at one of three doses (20 mg/d, n = 138 women; 40 mg/d, n = 137 women; or 80 mg/d, n = 140 women). Outcome variables that were assessed after 12 weeks of treatment included incontinence episode frequency recorded in a real-time diary and answers provided to the Patient Global Impression of Improvement scale and the Incontinence Quality of Life questionnaire. RESULTS Duloxetine was associated with significant and dose-dependent decreases in incontinence episode frequency that paralleled improvements that were observed in the Patient Global Impression of Improvement scale and the Incontinence Quality of Life questionnaire. The median incontinence episode frequency decrease with the use of the pooled diary analysis with placebo was 41% compared with 54% for duloxetine 20 mg per day (P =.06), 59% for duloxetine 40 mg per day (P =.002), and 64% for duloxetine 80 mg per day (P <.001). One half of the subjects at the 80 mg per day dose had a > or = 64% reduction in incontinence episode frequency (P <.001 vs placebo); 67% had > or = 50% reduction (P =.001 vs placebo). These improvements were observed despite significant concurrent dose-dependent increases in the average voiding interval in the duloxetine groups compared with the placebo group. Similar statistically significant improvements were demonstrated in a subgroup of 163 subjects who had more severe stress urinary incontinence (> or = 14 incontinence episode frequency per week; 49%-64% reduction in incontinence episode frequency in the duloxetine groups compared with 30% in the placebo group). Discontinuation rates for adverse events were 5% for placebo and 9%, 12%, and 15% for duloxetine 20, 40, and 80 mg per day, respectively (P =.04). Nausea was the most common symptom that led to discontinuation. None of the adverse events that were reported were considered to be clinically severe. CONCLUSION This trial provides evidence for the efficacy and safety of duloxetine as a pharmacologic agent for the treatment of stress urinary incontinence.
This paper references
10.1016/S0090-4295(99)80384-7
Quality of life of persons with urinary incontinence: development of a new measure.
T. Wagner (1996)
10.1097/00006205-199302000-00026
Urinary Incontinence in Adults: Clinical Practice Guideline
Rockville (1993)
10.1016/S0002-9378(98)70517-4
Evaluating the outcome of surgery for pelvic organ prolapse.
L. Wall (1998)
10.1016/S0022-5347(17)49637-6
Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter.
J. Gajewski (1984)
10.1056/NEJM200012213432501
Phenylpropanolamine and the risk of hemorrhagic stroke.
W. Kernan (2000)
10.2307/2529712
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
S. Pocock (1975)
10.1016/S0090-4295(99)00259-9
Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence
D. Gleason (1999)
10.4065/76.4.358
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
R. Appell (2001)
10.1002/(SICI)1520-6777(1998)17:3<249::AID-NAU9>3.0.CO;2-D
Standardization of outcome studies in patients with lower urinary tract dysfunction: A report on general principles from the standardisation committee of the international continence society
A. Mattiasson (1998)
10.1002/(SICI)1520-6777(1998)17:3<255::AID-NAU10>3.0.CO;2-J
Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction
G. Lose (1998)
10.1016/0014-2999(79)90023-2
Effects of clonidine on the lumbar sympathetic pathways to the large intestine and urinary bladder of the cat.
J. Krier (1979)
Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat.
K. Thor (1995)
10.1111/j.1600-0404.1980.tb01472.x
Effect of the alpha‐adrenergic blocking agent thymoxamine on the neurogenic bladder and urethra
E. Pedersen (1980)
10.1016/0006-8993(82)90865-4
Brain stem influences on the parasympathetic supply to the urinary bladder of the cat
S. McMahon (1982)
10.1016/S0006-8993(98)00401-6
Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats
Mary Jane Espey (1998)
10.1016/0165-3806(90)90062-4
Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N-dimethyltryptamine.
K. Thor (1990)
10.1111/j.1476-5381.1996.tb15378.x
Spinal 5‐HT2 receptor‐mediated facilitation of pudendal nerve reflexes in the anaesthetized cat
H. Danuser (1996)
10.1016/S0090-4295(98)00454-3
Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL)
D. Patrick (1999)
10.1016/S0090-4295(97)00599-2
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
R. Appell (1997)
10.1016/0014-2999(92)90788-6
Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats.
M. J. Espey (1992)
10.1016/0014-2999(91)90551-Z
Alpha 2-adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat.
J. Downie (1991)
Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats.
J. Downie (1988)



This paper is referenced by
10.1016/S0024-3205(02)01848-9
Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
M. Katofiasc (2002)
10.1097/01.YIC.0000182117.49887.E7
Urinary hesitancy and retention caused by ziprasidone.
Dimitris Xomalis (2006)
10.1007/s00192-008-0564-4
Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine
Maria Vella (2008)
10.1016/B978-0-12-374271-1.00040-X
Aging and the Lower Urogenital System
C. Dubeau (2010)
10.2174/1573411011107030184
Quantitative Analysis of Duloxetine and 1-Naphthol by Capillary Micellar Electrokinetic Chromatography
Nathalie R Wingert (2011)
10.1016/J.EURSUP.2004.10.005
Stress Urinary Incontinence in Women: Efficacy and Safety of Duloxetine
N. Zinner (2005)
10.1016/J.ICS.2005.01.011
Which sling for stress urinary incontinence
H.A.M. Vervest (2005)
10.1097/01.JU.0000080708.87092.CC
Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence
R. Dmochowski (2003)
Guidelines on Urinary Incontinence
F. Cruz (2015)
10.1007/s11255-006-0085-3
Dilemmas in the management of female stress incontinence: the role of pelvic floor muscle training
H. Konstantinos (2006)
10.1152/ajprenal.00523.2013
Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats.
Z. Schwen (2013)
10.1111/j.1464-410X.2004.04810.x
Clinical practice guidelines for the initial management of urinary incontinence in women: a European‐focused review
L. Viktrup (2004)
10.1016/j.ijgo.2004.05.009
Duloxetine: a new approach for treating stress urinary incontinence
K. Moore (2004)
10.1080/01443610701359621
Detrusor overactivity successfully treated with duloxetine
M. Basu (2007)
10.1007/978-3-319-62725-0_5
Theories of Toileting
Xinrui Jiang (2017)
Selecting medications for the treatment of urinary incontinence.
B. D. Weiss (2005)
10.1007/978-1-84628-510-3_8
Pharmacotherapy for stress urinary incontinence.
D. Castro-Díaz (2005)
10.1111/j.1464-410X.2006.06473_2.x
PREDICTIVE FACTORS OF RESOLUTION OF PRIMARY VESICO‐URETERIC REFLUX: A MULTIVARIATE ANALYSIS
P. Dewan (2006)
10.1097/01.AOG.0000134525.86480.0f
Pharmacological Treatment of Women Awaiting Surgery for Stress Urinary Incontinence
L. Cardozo (2004)
10.1016/J.CLINTHERA.2004.09.010
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
J. Greist (2004)
10.1097/01.SMJ.0000146587.06656.98
Stress Urinary Incontinence in Active Elderly Women
L. Viktrup (2005)
Duloxetine in the treatment of stress urinary
W. Jost (2005)
10.1097/01.JU.0000124909.31527.A9
Validation of a clinical algorithm to diagnose stress urinary incontinence for large studies.
I. Yalcin (2004)
10.1016/J.AMJOPHARM.2005.03.004
Duloxetine for management of stress urinary incontinence.
D. Guay (2005)
10.2165/00003495-200464140-00001
Pharmacotherapy for Stress Urinary Incontinence
Norman R. Zinner (2012)
10.1576/toag.7.2.117.27070
Duloxetine: the long awaited drug treatment for stress urinary incontinence
S. Orme (2005)
10.1016/B978-1-4160-6911-9.00068-2
Pharmacologic Management of Lower Urinary Tract Storage and Emptying Failure
K. Andersson (2012)
Nuevas perspectivas en el tratamiento del dolor neuropático: duloxetina
J. Pérez-Cajaraville (2006)
10.1016/J.JCHROMB.2007.02.025
Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma.
D. Satonin (2007)
10.1097/MD.0000000000018834
Evaluation of duloxetine and innovative pelvic floor muscle training in women with stress urinary incontinence (DULOXING)
Magdaléna Hagovska (2020)
10.1124/jpet.109.154963
Pharmacological Properties of 2-((R-5-Chloro-4-methoxymethylindan-1-yl)-1H-imidazole (PF-3774076), a Novel and Selective α1A-Adrenergic Partial Agonist, in in Vitro and in Vivo Models of Urethral Function
K. Conlon (2009)
10.1111/j.1471-0528.2006.00877.x
What do we know about duloxetine's mode of action? Evidence from animals to humans
B. Schuessler (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar